// App-Quantinova.ai

3567 : Final Report of a Phase I/II Study of Hyper-CVAD Plus RAD001 (Everolimus) in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Deborah A. Thomas

Principal Investigators

  • Farhad Ravandi

  • Hagop M. Kantarjian

  • Marina Konopleva

  • Michael E. Rytting

  • Marian R Love

  • Hongbo Lu

  • Rui-yu Wang

  • Rebecca Garris

  • Jorge E. Cortes

  • Susan O'Brien

  • Jan A. Burger

Medical Centers

  • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, Houston, TX

  • Lymphoma, MD anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Non-Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Hodgkin's Lymphoma

  • Mucositis

  • Lymphomas

  • Sepsis

  • B-cell acute lymphoblastic leukemia

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • Ph chromosome

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Phosphorylated-AKT

  • Serine/threonine-protein kinase mTOR

Drug/Treatment

  • Everolimus

Outcome

  • N/A

Study Design

  • pharmacokinetics

  • pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved